eikon therapeutics funding

eikon therapeutics funding

Grant ID: DP2-GM150017 SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is advancing breakthrough Dr. Ponces research program is aimed at discovering and characterizing the visual representations of the primate brain, using machine intelligence approaches. His newly formed research group at UC San Diego uses computational and experimental approaches to advance four-dimensional (4D) cell biology. Project Title: Unraveling the Telomere Black Box: A New Single-Molecule Approach to Define the Telomere Chromatin Landscape and its Functional Mechanisms Manipulating Epitope Immunodominance and Tracking B-cell-Antigen Interactions for Vaccine Design. In order to improve the control system between a robotic device and human user, Dr. Young research uses new artificial intelligence (AI) and deep learning techniques to enhance the capability of wearable robotic systems. By studying songbirds, the Gadagkar Lab aims to reveal the neural circuits for social behavior and communication. She received her Ph.D. in Clinical Psychology from Yale University and completed her predoctoral clinical internship at McLean Hospital/Harvard Medical School. Eikon Therapeutics Grant ID: DP2-AG082342. Project Title: Determining Age-Dependent Metabolic Changes in Tumors and Their Microenvironment Funded by the National Institute of General Medical Sciences. In 2013, Dr. Sanulli completed her Ph.D. at the Pierre and Marie Curie University in Paris, where she studied the mechanisms of gene silencing in development. Grant ID: DP2-NS132373. He received his Ph.D. from Colorado State University studying West Nile virus evolution and he completed his postdoc training at Scripps Research investigating the Zika epidemic. in Biological Sciences from Tsinghua University. Project Title: Chemical Control of Misfolded Protein Fate Grant ID: DP2-CA280626. in physics from Stanford university and a Ph.D. in biophysics from the University of California, Berkeley, where she studied how mechanical forces regulate nucleation in branched actin networks in the laboratory of Dr. Daniel Fletcher. Funded by the National Institute of General Medical Sciences. Berna received her B.S. Grant ID: DP2-AI175474. Funded by the National Institute of Mental Health. Update 01/07/2022: Eikon Therapeutics has raised $518 million in Series B funding to accelerate platform development and advance multiple discovery programs. Eikons foundational technology is very different from anything Ive seen, says Dror Berman, partner of Innovation Endeavors, which was one of the VC firms that helped incubate Eikon. Project Title: Synthetic Metabolism to Armor and Enhance a New Class of Cell Therapies She completed postdoctoral training in molecular biophysics at UT Southwestern Medical Center, where she worked with Dr. Michael Rosen to determine how phase separation regulates signaling molecules at the plasma membrane. Eikon has bolstered its team with Perlmutters one-time colleagues at Merck. He then moved to Germany to pursue his education in bioengineering at the University of Dortmund and transferred to Syracuse University. Prior to receiving the NIH Directors New Innovator Award, Steven has received an NIH Pathway to Independence Award (K99/R00) from the National Heart, Lung, and Blood Institute (NHLBI), an American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award, and a Gilead Research Scholars Award in Cardiovascular Comorbidities. Eikon Therapeutics, the startup helmed by former Merck research chief Roger Perlmutter, has acquired several experimental medicines from fellow privately-held drugmakers, the company announced Thursday. in biology at Tsinghua University in Beijing, China. This first Series C close brings Eikons total capital raised to nearly $775 million since its founding in late 2019. Her work has been supported by a K23 Mentored Patient-Oriented Research Career Development Award from the National Heart, Lung, and Blood Institute. Ina addition to the NIH Directors New Innovator Award, Denise is a recipient of the CASI award from the Burroughs Wellcome Fund and the NSF CAREER award. While in the Baltimore lab, he began working on cell engineering using chimeric receptors and created a cell-based T cell epitope discovery method. Project Title: THWART-TB : Testing Health Workers At Risk to Advance OurUnderstanding of TB Infection The use of this approach, called liquid biopsies, combined with insights from tumor genome analysis, will be critical to uncover causes of treatment resistance, discover novel genetic biomarkers from the blood, and develop non-invasive applications for cancer precision medicine. Funded by the National Institute of Mental Health. How Does Neuromodulation Shape the Fluidity of Spatial Working Memory? Eikon Therapeutics has raised a total of $666M in funding over 3 rounds. She obtained her PhD at University of California San Francisco, in the lab of Jonathan Weissman, where she pioneered a high-throughput approach to measure RNA structure in cells. Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 million. Project Title: Improving Drug Design to Eliminate Side Effects: From Computational to Animal Models Funding He received a Ph.D. in Biomedical Engineering from Duke University for his work with Ashutosh Chilkoti, where he uncovered sequence heuristics to program the phase separation behavior of intrinsically disordered protein protein-polymers. In addition to the NIH Directors New Innovator Award, her lab is also supported by the Damon Runyon Foundation and career development awards from the National Cancer Institute and the American Association for Cancer. HAYWARD, Calif. January 6, 2022 Eikon Therapeutics, Inc., a With the new round of funding, the company intends to expand its capabilities by doubling its current workforce of 100 employees and build out more of its physical infrastructure. So far this year, at least 46 biotechs have raised rounds of $100 million or more, per Crunchbase data. Grant ID: DP2-GM149554 Grant ID: DP2-GM149750. Eikon is delighted to partner with Impact scientists to help develop IMP1734 and other selective PARP1 inhibitors that exploit DNA damage response aberrations often found in tumors to selectively kill cancer cells," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics. Johannes Schneberg is an Assistant Professor in the Departments of Pharmacology and Chemistry and Biochemistry at the University of California San Diego. In addition to the NIH Directors New Innovator Award, Aditya is fortunate to have received an Emerging Leaders in Biosecurity Initiative Fellowship, the 35 Under 35 Award from the American Institute of Chemical Engineers, the 2021 Langer Prize for Innovation and Entrepreneurial Excellence, a New Innovator Award from the Foundation for Food and Agriculture Research, and an Office of Naval Research Young Investigator Award. Grant ID: DP2-GM150019 As an NIH-IRACDA postdoctoral fellow at Emory University School of Medicine, she used molecular dynamics simulations to study ligand regulation and functional evolution in nuclear receptors. Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering and science. The companys Scientific Advisory Board (SAB) includes Betzig, who is a co-founder of Eikon Therapeutics. Silvi Rouskin is currently an Assistant Professor in the Department of Microbiology at Harvard Medical School. Sergey completed his PhD in neurosciences at Stanford University in 2016, where he studied motor cortical control of reaching and developed brain-computer interfaces in a preclinical monkey model in the lab of Prof. Krishna Shenoy. Chao Wang is currently an associate professor in the School of Electrical, Computer & Energy Engineering (ECEE) and affiliated with the Biodesign Center for Molecular Design & Biomimetics at Arizona State University (ASU). and Ph.D. degrees in Chemical Engineering from UT-Austin and MIT, and he then conducted post-doctoral research at Harvard Medical School in the laboratory of George Church. Project Title: New Insights Into the Molecular Regulation of Mechanotransduction Ione Fine and Ariel Rokem at the University of Washington was recognized with a NEI K99/R00 Pathway to Independence Award. Grant ID: DP2-GM150021. His lab uses an interdisciplinary approach to understand the mechanisms of human telomere replication and maintenance. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering and science. View contact profiles from Topics covered: startup launches, funding, IPOs and much more. this Story? Grant ID: DP2-MH132944 Aditya Kunjapur is an Assistant Professor in Chemical & Biomolecular Engineering at the University of Delaware, which he joined in December 2018. 'How can you understand life if you don't look at it live?' Eikon Project Title: The Female Songbird as a Novel Mechanistic Model for the Neural Basis of Social Evaluation For this global powerhouse to choose Tucson for its new state-of-the-art manufacturing and sterilization facility is big news. She then gained experience in cell engineering, quantitative single cell analysis, and mathematical modeling of biological circuits as a postdoctoral fellow at California Institute of Technology in the laboratory of Michael Elowitz. 05-05-2021 Eikon Therapeutics, a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. Eikon Therapeutics announced three business development deals on Thursday, effectively dropping in a pipeline of cancer drugs alongside more than $100 million in fresh funding. As a postdoctoral fellow with Dr. Alexander Schier, she studied the genes involved in complex neuropsychiatric disorders, generating over a hundred zebrafish mutants for schizophrenia-associated genes and assessing their brain activity, brain structure, and behavior. We thank the company for its continued commitment to our state. site you are consenting to these choices. He then pursued post-doctoral research with Dr. Jennifer Lippincott-Schwartz at HHMI Janelia Research Campus interrogating the molecular basis of inter-organelle fatty acid and protein trafficking. This approach requires the integration of tools that support advanced imaging, high-performance computing, molecular and cellular biology, medicinal chemistry, and robotics. Dr. Niepa is an Assistant Professor of Chemical and Petroleum Engineering at the University of Pittsburgh. Project Title: Deciphering Principles of Human Embryonic Patterning in Development and Disease Project Title: Uncovering Brain-Wide Molecular Determinants of Individual Memory Performance Across Lifespan Stock Market | FinancialContent Business Page The Sen laboratory investigates the regulation of T cell dysfunction and explores epigenetic approaches for T cell engineering. Grant ID: DP2-CA280622. Grant ID: DP2-NS132372. Series A investors The Column Group, Foresite Capital, Lux Capital, Horizons Ventures and Innovation Endeavors also participated in the Series B round. One deal gives Eikon a set of cancer drug prospects from startup Seven and Eight Biopharmaceuticals, one of which is in Phase 2 testing in cancer patients with solid tumors. Eikon Therapeutics Dr Areys research program focuses on defining the molecular underpinnings of complex behaviors, which combines her multidisciplinary training in genetics, genomics, molecular and behavioral neuroscience in multiple model systems. Dr. Ruvandhi Nathavitharana is an Assistant Professor at Beth Israel Deaconess Medical Center and Harvard Medical School. In addition to the NIH Directors New Innovator Award, research in the Feder lab is also supported by the Gilead Research Scholars Program in HIV. The Bay Area-based biotech made another splash Thursday, announcing a $106 million Series C raise and the acquisition of exclusive, global rights to several early- to mid-stage assets. This, he says, means he wont have to interrupt his team every few months to help solicit investment. Born in Bulgaria in a family of rock musicians, Silvi immigrated to the USA by herself to pursue a career in science at the age of 15. Grant ID: DP2-GM149556 BD joins Roche Tissue Diagnostics, Accelerate Diagnostics, HTG Molecular and other companies here doing cutting-edge work to help solve our country's greatest challenges. Grant ID: DP2-GM149551 Project Title: Annotated Lineage Trees of Murine Development Project Title: Harnessing the Chromatin Conformational Code for Epigenetic Regulation Use the PitchBook Platform to explore the full profile. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to measure the real-time movement of individual proteins and protein populations in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Dr. Clites currently directs the Anatomical Engineering Group at UCLA. Grant ID: DP2-GM149552 Biochemical regulation requires dynamic, short-lived interactions among intracellular constituents. $665.8M Investors Count 18 Funding, Valuation & Revenue 3 Fundings Eikon Therapeutics's latest funding round was a Series B for $517.8M on January 6, ", Judy Rich, president & CEO, TMC HealthCare and chair of the board, Sun Corridor Inc., said,"BD has a long history of commitment to public health and is deeply involved in many aspects of the nation's COVID response. Eikon Therapeutics Stock Price, Funding, Valuation, Revenue Project Title: Genomic tools for massively parallel recording of signaling activity at cellular resolution in a brain-wide manner He continued his training with Drs. 2003) at the Massachusetts Institute of Technology, applied physics (Ph.D. 2011) at Caltech, medicine (M.D. Dr. Grubaugh is currently an Associate Professor in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health. IMPACT Therapeutics can be found via the website. She received her B.S. Project Title: Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma Grant ID: DP2-HL168071. Caroline Uhler is a core institute member of the Broad Institute of MIT and Harvard, where she co-directs the Eric and Wendy Schmidt Center, and she is a Full Professor in the Department of Electrical Engineering and Computer Science and the Institute for Data, Systems, and Society at MIT. ", Sandra Watson, Arizona Commerce Authority President & CEO, said, "We're excited to see global innovator BD select Tucson for this new operation. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo. She completed her graduate training in cell biology through a joint program between the University of North Carolina and the National Institutes of Health, working with Dr. Clare Waterman to study integrin receptors and the actin cytoskeleton with superresolution light microscopy. Previously, he established novel optical and ultrasound-based imaging techniques for the visualization of life-threatening ventricular arrhythmias. Chris then completed his postdoctoral training at Stanford University where he interrogated neural circuits in epilepsy using state-of-the-art genetic, electrophysiological, and optical methods under the mentorship of Dr. John Huguenard. Project Title: A Novel Approach to Crack Neuronal Mechanisms that Shape Computations in the Brain Stock Market | FinancialContent Business Page Eikon is now following with a round that values the company at a meaningful step-up to a nearly $518 million Series B and includes several new strategic investors, Perlmutter said. January 06, 2022 07:00 AM Eastern Standard Time HAYWARD, Calif.-- ( BUSINESS WIRE )--Eikon Therapeutics, Inc., a pioneer in the application of live-cell Project Title: Life History of the Menstruating Uterus The Chan lab integrates computational and experimental methods to characterize the mammalian cell fate map with a focus on understanding how robustness is encoded in the process of development. This is a BETA experience. Its going ok so far. At Caltech, his research group develops new technologies at the intersection of imaging, genomics, and machine learning to produce quantitative measurements of living systems with single-cell resolution. Grant ID: DP2-AI176139. Dr. Aaron Whiteley is an Assistant Professor in the Department of Biochemistry at the University of Colorado Boulder. Evgeny Kvon is an Assistant Professor in the Department of Developmental and Cell Biology at the University of California, Irvine. In addition to the NIH Directors New Innovator Award, Dr. Blazeck has received a Beckman Young Investigator Award and an American Cancer Society Postdoctoral Fellowship. Jan Christoph is an Assistant Professor at the University of California, San Francisco, where he leads the Cardiac Vision Laboratory. The Column Group invested in Eikon Therapeutics's Series B funding round. from HMS and his Ph.D. in neuroscience from the Harvard Graduate School of Arts and Sciences, working in the laboratory of Richard T. Born, where he was supported by an NIH Individual Predoctoral Fellowship. He received his Ph.D. from Tsinghua University where he studied the molecular mechanisms governing pluripotent stem cell fate decisions in Dr. Ye-Guang Chens lab. Eikon Therapeutics Project Title: Defining mechanisms for natural vision in the primate brain with machine learning By deeply engaging with issues of measurement and methodology, it examines the complex relationships between social categories and social inequality; and extends into topics such as social demography, health, aging, race/ethnicity & technology (e.g., artificial intelligence, machine learning, and computer vision), social psychology, sociology of the body, and comparative & historical sociology. Grant ID: DP2-HL168072. At the Allen Institute, Xiaoyin's team is focusing on further developing in situ sequencing-based neuroanatomical techniques and applying them to understand the development and evolution of brain circuits. Grant ID: DP2-HL168563. As a Ph.D. student with Dr. David Baker, she engineered biomolecular interactions, providing the foundation and skills for her long-term goals of developing new therapeutics for these disorders. She then joined the laboratory of Dr. William Greenleaf and collaborated with Dr. Aaron Straight as a postdoc at Stanford University, to develop novel technologies for studying the structure of chromatin and chromatin-associated RNAs. She received her B.S. In addition to the NIH Directors New Innovator Award, Dr. Nathavitharana is the recipient of an NIH K23 Career Development Award, an American Society for Tropical Medicine and Hygiene Burroughs Wellcome Fellowship, the Union North America Region Early Investigator Award, and the Stephen Lawn TB-HIV Research Leadership Prize. Grant ID: DP2-DE032725. Debattama (Deb) Sen is an Assistant Professor at Harvard Medical School and Principal Investigator in the Center for Cancer Research at Massachusetts General Hospital. our sites and services. Eikon Therapeutics announced three business development deals on Thursday, effectively dropping in a pipeline of cancer drugs alongside more than $100 million in fresh funding. To address this critical need, Dr. Young works to identify ways to optimize robotic technologies physically improve human mobility and outcomes. Project Title: Unlocking the Postnatal Human Brain Using Activity Augmented Organoids Conroy continued, "Tucson's economic transformation is a national success story, and BD is excited to be part of it. She is an Editorial Board member at Neurology and an Associate Editor of Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. At UCSB, Michael leads an interdisciplinary research group focused on the computational modeling of human, animal, computer, and prosthetic vision to elucidate the neuroscience behind bionic technologies that may one day restore useful vision to people living with incurable blindness. Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, announced that it has closed a $517.8 million Series B financing. Which means they can be more focused on developing new drugs. One of the physicists who co-founded Eikon, Eric Betzig, was part of the group that won the 2014 Nobel Prize in Chemistry for its discovery. Project Title: Compliant Limb Reconstruction: Co-engineering Body and Machine to Revolutionize Limb Salvage Grant ID: DP2-DK136278. The companys tools, says Perlmutter, have been used to evaluate about 70 different proteins found in different types of cells that it can observe with its microscopes. ElevateBio raises $401M Series D in the largest biotech Specifically, his group studies the link between mitochondrial dynamics and diseases that are caused by mitochondrial dysfunction such as intestinal diseases, epilepsy, and dementia, using adaptive optics lattice light-sheet microscopy, organoids, human-induced pluripotent stem cells, computer simulations, and machine learning. Yvette Fisher is an Assistant Professor of Neurobiology in the Molecular & Cell Biology Department and Helen Wills Neuroscience Institute at University of California Berkeley and a Chan Zuckerberg Biohub Investigator. Eikon Therapeutics, which develops applications to apply live-cell super-resolution microscopy to drug discovery, announced in January that it raised $518 million in Series B financing. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Project Title: Scalable Development of Custom Genome Editing Technologies in physics, chemistry, and mathematics from Bangalore University, M.S. Project Title: Biology and Applications of Mammalian Hibernation-Like States TUCSON, Ariz., April 1, 2021 /PRNewswire/ --BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's supply chain, serving as a final-stage manufacturing and sterilization center. Alongside its funding, the company announced deals for drug candidates from three biotech companies, each of which are in various phases of clinical stage testing. in Chemistry at Xiamen University, China, and Ph.D. in Bioorganic Chemistry at Michigan State University mentored by Prof. Babak Borhan, followed by postdoctoral training at the Massachusetts Institute of Technology and Stanford University, mentored by Prof. Alice Ting. Len Pennacchio and Axel Visel at Berkeley lab, where he investigated the molecular basis of vertebrate evolution and human congenital disorders. AJ subsequently joined the University of Oxford as Marie Curie/Rubicon fellow and Henry Welcome fellow to study influenza virus replication in the laboratories of Prof Ervin Fodor and Prof Achilles Kapanidis, and to teach at Lincoln College, Oxford, as Kemp Research fellow. Grant ID: DP2-MH132939. His research interests include cardiac electrophysiology and biomechanics, cardiac arrhythmia mechanisms, the physics of complex biological systems, numerical modelling, artificial intelligence and imaging. He completed a postdoctoral fellowship at the University of California, Berkeley, where he was also a Berkeley Institute for Data Science (BIDS) fellow. Vikram is a recipient of the Searle Scholar Award, the Peter and Patricia Gruber International Research Award in Neuroscience, the NIH K99/R00 Pathway to Independence Award, and the Simons Collaboration on the Global Brain Postdoctoral Fellowship. Eikon Therapeutics Raises $517.8 Million Series B Funding to Advance Invention of New Medicines Posted Jan 13, 2022 by GoPhotonics Editorial Team Eikon Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines. She obtained her Ph.D. at the University of Toronto studying alternative splicing in the nervous system. On Thursday, Eikon announced that it had raised a $517.8 million Series B round, making for a total of $668 million raised by the company to date. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering This work lies at the interface of human immunology, systems biology, and functional epigenomics merging clinical observations with mechanistic mouse studies to develop novel therapeutic strategies. ET, ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein, Big pharmas looming threat: a patent cliff of tectonic magnitude, Startup Eikon, led by Merck vets, buys drugs from three biotechs and banks another $106M, Medicare keeps limits on Alzheimers drug coverage, but loosens policy, Sanofi drug, acquired from a startup, shows early potential in MS, FDA clears narrow use of Lynparza in early prostate cancer, continuing shift on PARP drugs, The latest developments on the gene therapy frontier, Big Pharma keeps on coming to Boston: Thats where the action is, FTC Chair Lina Khan Investigation Launched by US House Committee, Biden plans to pick physician Mandy Cohen to lead CDC, Extending Genetic Services Across Clinical Specialties to Improve Proactive Care, Telegenetics and the Changing Needs of Biopharma Clinical Trials, Biohaven sends latest drug to FDA, despite past trial setback, Rain Oncology to cut workforce by 65% after study failure. Project Title: Unraveling the genetic basis of cellular behaviors with deep learning and imaging-based reverse genetics Project Title: Spacially Mapping of Pooled In Vivo CRISPR Screens in the Tumor Microenvironment The Hayward, California-based biotechnology company also raised $106 million in the first close of a Series C round, bringing the companys total funding to nearly $775 million since its public debut two years ago.

Bilateral Fdi Data Unctad, Global Recruitment Agency Abu Dhabi, Certified Security Project Manager Practice Test, Articles E